CRM Publications

Kotelevtsev Y, Brown WR, Fleming S, Kenyon CJ, Edwards CR, Seckl JR, Mullins JJ.  1999.  Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2.J Clin Invest. 103(5):683-9.

Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR et al..  1997.  11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress.Proc Natl Acad Sci U S A. 94(26):14924-9.

Chapman KE, Kotelevtsev Y, Jamieson PM, Williams LJ, Mullins JJ, Seckl JR.  1997.  Tissue-specific modulation of glucocorticoid action by the 11 beta-hydroxysteroid dehydrogenases.Biochem Soc Trans. 25(2):583-7.

Brown WR, Chapman KE, Kotelevtsev Y, Yau JL, Lindsay RS, Brett L, Leckie C, Murad P, Lyons V, Mullins JJ et al..  1996.  Cloning and production of antisera to human placental 11 beta-hydroxysteroid dehydrogenase type 2.Biochem J. 313 ( Pt 3):1007-17.

Brown WR, Diaz R, Robson AC, Kotelevtsev Y, Mullins JJ, Kaufman MH, Seckl JR.  1996.  The ontogeny of 11 beta-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor gene expression reveal intricate control of glucocorticoid action in development.Endocrinology. 137(2):794-7.